SDV2102 / Syndivia, GSK - LARVOL DELTA

Preclinical evaluation of SDV2102, a novel PSMA-targeting DAR1 ADC for mCRPC treatment (AACR 2025) - "SDV2102 achieved a therapeutic index of 38, representing a substantial safety margin. These preclinical results support the advancement of SDV2102 into clinical trials as a promising therapeutic candidate for the treatment of mCRPC."

Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1